ORBCEL-M and Nephstrom In the Spotlight

The Nephstrom project and the promise of Orbsen’s stromal cell therapy are up for discussion when RegMedNet interviews Remedi Chair (and Orbsen Director), Professor Timothy O’Brien.

“Funded by a €6-million grant from the European Union Horizon 2020 programme and including many partners, the project is now setting up a stem cell factory with the NHS in Liverpool (UK) and will be conducting a clinical trial of its allogeneic bone marrow stromal cell product (ORBCEL-M) in 48 Type 2 diabetes patients at high risk of developing diabetes-related kidney problems, in the hope of reducing kidney inflammation and improving kidney function.”

Read the story, including the Q&A with Prof O’Brien at RegMedNet.

2015-12-01T10:45:28+00:00 November 18th, 2015|